PRDX1 knockdown promotes erastin-induced ferroptosis and impedes diffuse large B-cell lymphoma development by inhibiting the MAPK/ERK pathway
- Chuanming Lin 1,2, Shuiling Xie 1, Menger Wang 3, Jianzhen Shen 4
- Chuanming Lin 1,2, Shuiling Xie 1, Menger Wang 3
- 1Department of Hematology, First Affiliated Hospital of Gannan Medical University, No. 128, Jinling Road, Economic Development District, Ganzhou City, Jiangxi Province, 341000, China.
- 2Fujian Medical University Union Hospital, No. 29, Xinquan Road, Gulou District, Fuzhou City, Fujian Province, 350001, China.
- 3Gannan Medical University, Rongjiang New District University Park, Ganzhou City, Jiangxi Province, 341099, China.
- 4Fujian Medical University Union Hospital, No. 29, Xinquan Road, Gulou District, Fuzhou City, Fujian Province, 350001, China. fjxhsjz@163.com.
- 0Department of Hematology, First Affiliated Hospital of Gannan Medical University, No. 128, Jinling Road, Economic Development District, Ganzhou City, Jiangxi Province, 341000, China.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Knocking down peroxiredoxin 1 (PRDX1) enhances ferroptosis in diffuse large B-cell lymphoma (DLBCL) cells by inhibiting the MAPK/ERK pathway. This finding suggests PRDX1 as a potential therapeutic target for DLBCL treatment.
Area Of Science
- Oncology
- Cell Biology
- Molecular Mechanisms
Background
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematological malignancy.
- DLBCL cells exhibit sensitivity to ferroptosis, a regulated form of cell death.
- Peroxiredoxin 1 (PRDX1) is implicated in cellular processes relevant to cancer progression.
Purpose Of The Study
- To investigate the role of PRDX1 in ferroptosis within DLBCL.
- To elucidate the molecular mechanisms by which PRDX1 influences ferroptosis and DLBCL progression.
Main Methods
- PRDX1 expression analysis in DLBCL tissues and cells via bioinformatics and qPCR.
- In vitro assessment of PRDX1's impact on DLBCL cell proliferation, apoptosis, migration, invasion, and ferroptosis.
- In vivo validation using a xenograft tumor model.
- Transcriptome sequencing to identify PRDX1-mediated pathways and MAPK/ERK pathway modulation using anisomycin.
Main Results
- PRDX1 expression is upregulated in DLBCL.
- PRDX1 knockdown inhibits DLBCL cell proliferation, migration, invasion, and tumor growth, while promoting apoptosis.
- PRDX1 knockdown enhances erastin-induced ferroptosis, indicated by increased iron and MDA, and decreased GSH, COX2, GPX4, and SLC7A11 protein levels.
- PRDX1 knockdown reduces MAPK/ERK pathway phosphorylation, an effect reversed by anisomycin.
Conclusions
- PRDX1 knockdown promotes ferroptosis and hinders DLBCL progression by inhibiting the MAPK/ERK pathway.
- Targeting PRDX1 represents a potential therapeutic strategy for DLBCL.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
02:23
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
01:07
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

